Overview

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

Status:
Terminated
Trial end date:
2018-01-16
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the impact on quality of life of Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard care alone, in subjects affected by inoperable malignant bowel obstruction.
Phase:
Phase 2
Details
Lead Sponsor:
Ipsen
Treatments:
Angiopeptin
Lanreotide
Somatostatin